AmVac Confirms Cooperation With German GFE Blut mbH

ZUG, Switzerland, July 20, 2015 /PRNewswire/ --

Production of Sendai virus for testing kits to determine viral contamination 

GFE Blut mbH (Company for Research, Development and Distribution of Diagnostics for Blood Donation Testing) is a subsidiary undertaking of several blood donation services of the German Red Cross and the Bavarian Red Cross, whereas GFE Blut is providing contract research to its shareholders, especially regarding research and development of diagnostic procedures and automation solutions for the blood donor area.

For the development of specialised testing kits for determining viral contaminations, GFE Blut requires Sendai virus material according to particular specifications and quality criteria.

AmVac and GFE Blut concluded an agreement according to which AmVac Research GmbH in Martinsried, Germany, will produce and deliver that viral material to GFE Blut.

AmVac is proud to have been selected as the provider of choice by institutions of the Red Cross and is looking forward to the collaboration with GFE Blut.

Zug, July 20, 2015

AmVac - Tomorrow's Vaccines Today 

AmVac AG is a biopharmaceutical company developing and marketing innovative vaccines. The life-science company was founded in 2005, is headquartered in Zug, Switzerland and has research laboratories in Germany and Italy, and a manufacturing operation in Hungary. Based on exclusive licenses from leading German scientific institutes of the Helmholtz- and Max-Planck societies and own IP, AmVac has developed an innovative portfolio of seven vaccine candidates and three platform technologies - Lactobacillus, Sendai and Malp. The most advanced product of AmVac is Gynevac, based on the Lactobacillus platform. Previously already approved for selected indications in certain geographies, the product is currently being developed for the treatment of certain highly prevalent urogenital diseases on a broad international level. With its particularly favourable safety profile, Gynevac could, for the first time, offer an effective treatment or prevention of non-malignant prostate enlargement and inflammation as well as of bacterial inflammation, virtually free of side effects.

Contact
AmVac Investor Relations
T +41-41-725-32-30
ir@amvac.eu